Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Scientists identify common cause of all forms of amyotrophic lateral sclerosis

Scientists identify common cause of all forms of amyotrophic lateral sclerosis

Researchers to generate new knowledge about brain's complex communication system

Researchers to generate new knowledge about brain's complex communication system

NIA awards UK Sanders-Brown Center on Aging ADC to continue Alzheimer's research

NIA awards UK Sanders-Brown Center on Aging ADC to continue Alzheimer's research

New Therapy Grants Program supports innovative approach to treat epilepsy

New Therapy Grants Program supports innovative approach to treat epilepsy

Seven research teams across the U.S. to develop new drugs for nervous system disorders

Seven research teams across the U.S. to develop new drugs for nervous system disorders

Powerful X-rays help develop new drug treatment for malignant melanoma

Powerful X-rays help develop new drug treatment for malignant melanoma

DiaGenic reports operating revenue of NOK 1,151 thousand for second quarter 2011

DiaGenic reports operating revenue of NOK 1,151 thousand for second quarter 2011

NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy

NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy

Medical research funding boost in UK

Medical research funding boost in UK

Cortex second quarter net loss decreases to $356,000

Cortex second quarter net loss decreases to $356,000

Vitamin C shows promise against Alzheimer's disease

Vitamin C shows promise against Alzheimer's disease

Researchers to unravel how brain makes everyday prognostications

Researchers to unravel how brain makes everyday prognostications

Positive link between fish oil supplements and cognitive function

Positive link between fish oil supplements and cognitive function

Ultrasound can predict high risk of stroke in patients with asymptomatic carotid stenosis

Ultrasound can predict high risk of stroke in patients with asymptomatic carotid stenosis

Researchers document how immune system can counteract advancement of Alzheimer's

Researchers document how immune system can counteract advancement of Alzheimer's

Study reveals structure of ribosomal assembly intermediate

Study reveals structure of ribosomal assembly intermediate

Moderate social drinking reduces risk of dementia and cognitive impairment

Moderate social drinking reduces risk of dementia and cognitive impairment

Modified Cdk5 enzyme triggers damage to nerve cell connections in human Alzheimer's brains

Modified Cdk5 enzyme triggers damage to nerve cell connections in human Alzheimer's brains

Gene therapy cocktail can treat inherited diseases with 'misfolded' proteins

Gene therapy cocktail can treat inherited diseases with 'misfolded' proteins

Survey: 35% of people in the UK fear cancer more than other life-threatening conditions

Survey: 35% of people in the UK fear cancer more than other life-threatening conditions

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.